Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer Impact on Diagnosis, Staging, Evaluation of Treatment Response, and Detection of Recurrence

Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer... ORIGINAL ARTICLE Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer Impact on Diagnosis, Staging, Evaluation of Treatment Response, and Detection of Recurrence Akinori Asagi, MD,* Koji Ohta, MD, PhD,Þ Junichirou Nasu, MD, PhD,* Minoru Tanada, MD,Þ Seijin Nadano, MD,* Rieko Nishimura, MD, PhD,þ Norihiro Teramoto, MD, PhD,þ Kazuhide Yamamoto, MD, PhD,§ Takeshi Inoue, MD, PhD,|| and Haruo Iguchi, MD, PhD* of patients with pancreatic cancer was almost equal to the Objectives: Fluorodeoxyglucose (FDG)Ypositron emission tomogra- number of pancreatic cancerYrelated deaths. However, a slight phy/contrast-enhanced computed tomography (PET/CE-CT) involving improvement in survival has been observed with the introduc- whole-body scanning first by nonYCE-CT and FDG-PET followed by tion of gemcitabine and S-1 as chemotherapeutic medications 3,4 CE-CT has been used for detailed examination of pancreatic lesions. We for pancreatic cancer. Given this situation, clinical practice evaluated PET/CE-CT images with regard to differential diagnosis, stag- guidelines for pancreatic cancer have recently been established ing, treatment response, and postoperative recurrence in pancreatic cancer. in Japan, and treatment regimens are determined on the basis of Methods: Positron emission tomography/CE-CTwas conducted in 108 the extent of pancreatic cancer, which is evaluated by imaging. patients with pancreatic cancer and in 41 patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pancreas Wolters Kluwer Health

Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer Impact on Diagnosis, Staging, Evaluation of Treatment Response, and Detection of Recurrence

Pancreas , Volume 42 (1) – Jan 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/utility-of-contrast-enhanced-fdg-pet-sol-ct-in-the-clinical-management-tCe0rh0NPO

References (30)

Copyright
Copyright © 2012 by Lippincott Williams & Wilkins
ISSN
0885-3177
eISSN
1536-4828
DOI
10.1097/MPA.0b013e3182550d77
pmid
22699206
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer Impact on Diagnosis, Staging, Evaluation of Treatment Response, and Detection of Recurrence Akinori Asagi, MD,* Koji Ohta, MD, PhD,Þ Junichirou Nasu, MD, PhD,* Minoru Tanada, MD,Þ Seijin Nadano, MD,* Rieko Nishimura, MD, PhD,þ Norihiro Teramoto, MD, PhD,þ Kazuhide Yamamoto, MD, PhD,§ Takeshi Inoue, MD, PhD,|| and Haruo Iguchi, MD, PhD* of patients with pancreatic cancer was almost equal to the Objectives: Fluorodeoxyglucose (FDG)Ypositron emission tomogra- number of pancreatic cancerYrelated deaths. However, a slight phy/contrast-enhanced computed tomography (PET/CE-CT) involving improvement in survival has been observed with the introduc- whole-body scanning first by nonYCE-CT and FDG-PET followed by tion of gemcitabine and S-1 as chemotherapeutic medications 3,4 CE-CT has been used for detailed examination of pancreatic lesions. We for pancreatic cancer. Given this situation, clinical practice evaluated PET/CE-CT images with regard to differential diagnosis, stag- guidelines for pancreatic cancer have recently been established ing, treatment response, and postoperative recurrence in pancreatic cancer. in Japan, and treatment regimens are determined on the basis of Methods: Positron emission tomography/CE-CTwas conducted in 108 the extent of pancreatic cancer, which is evaluated by imaging. patients with pancreatic cancer and in 41 patients

Journal

PancreasWolters Kluwer Health

Published: Jan 1, 2013

There are no references for this article.